study for the early evaluation of the response to treatment with Cisplatin, Gemcitabine and Bevacizumab in patientes with advanced or metastatic non small cell lung cancer.

Phase IV/II open label study for the early evaluation of the response to treatment with Cisplatin, Gemcitabine and Bevacizumab in patientes with advanced or metastatic non small cell lung cancer. - IMPACT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-000459-15-ES

Enrollment

Unknown

Registered

2012-03-29

Start date

2012-06-07

Completion date

Unknown

Last updated

2016-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: Avastin 25 mg/ml concentrado para solución para perfusión (VIAL 100MG/4ML) Product Name: BEVACIZUMAB Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Spain

Contacts

Public ContactNoemi Reguart

Noemi Reguart

nreguart@clinic.ub.es34932275402na

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026